Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy | Zendy

Robert N. Foley | Zendy; Bryan M. Curtis | Zendy; Patrick S. Parfrey | Zendy

Open Access

Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy

Author(s) -

Robert N. Foley,

Bryan M. Curtis,

Patrick S. Parfrey

Publication year - 2008

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.02100508

Subject(s) - medicine , hazard ratio , epoetin alfa , hemodialysis , hemoglobin , confidence interval , dialysis , erythropoietin , blood transfusion , kidney disease , anemia , population , surgery , environmental health

Optimal hemoglobin targets for chronic kidney disease patients receiving erythropoiesis-stimulating agents remain controversial. The effects of different hemoglobin targets on blood transfusion requirements have not been well characterized, despite their relevance to clinical decision-making.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research